Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Maintains Neutral on Bionomics

HC Wainwright & Co. Maintains Neutral on Bionomics

HC Wainwright & Co. analyst Joseph Pantginis maintains Bionomics (NASDAQ:BNOX) with a Neutral.

byBenzinga Newsdesk

March 9, 2023

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis maintains Bionomics (NASDAQ:BNOX) with a Neutral.

Analyst Ratings

Citigroup Maintains Buy Rating for Hess Midstream: Here’s What You Need To Know

By Benzinga Insights

July 12, 1:00 PM

Citigroup has decided to maintain its Buy rating of Hess Midstream (NYSE:HESM) and raise its price target from…

HESM

Analyst Ratings

Forecasting The Future: 8 Analyst Projections For Prudential Financial

By Benzinga Insights

April 25, 11:00 AM

Analysts’ ratings for Prudential Financial (NYSE:PRU) over the last quarter vary from bullish to bearish, as provided by…

PRU

Why Teva Pharmaceuticals Stock Is Soaring After Hours

By Adam Eckert

July 26, 5:40 PM

Teva Pharmaceutical Industries (NYSE: TEVA) shares are surging in Tuesday's after-hours session after the company reported better-than-expected financial results.

TEVA

Morgan Stanley Assumes Fifth Third Bancorp at Equal-Weight, Announces Price Target of $37

By Benzinga Newsdesk

December 5, 10:13 AM

Morgan Stanley analyst Manan Gosalia assumes Fifth Third Bancorp (NASDAQ:FITB) with a Equal-Weight rating and announces Price Target of $37.

FITB

HC Wainwright & Co. Maintains Neutral on Bionomics

Related Posts

Citigroup Maintains Buy Rating for Hess Midstream: Here’s What You Need To Know

Forecasting The Future: 8 Analyst Projections For Prudential Financial

Why Teva Pharmaceuticals Stock Is Soaring After Hours

Morgan Stanley Assumes Fifth Third Bancorp at Equal-Weight, Announces Price Target of $37